» Articles » PMID: 28966081

Patterns of Care and Outcomes of Proton and Eye Plaque Brachytherapy for Uveal Melanoma: Review of the National Cancer Database

Overview
Journal Brachytherapy
Specialty Radiology
Date 2017 Oct 3
PMID 28966081
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To examine national practice patterns and outcomes of eye plaque brachytherapy compared to proton external beam radiotherapy in the treatment of choroid melanoma.

Methods And Materials: Demographic and clinical data for 1224 patients with choroid melanoma treated with either brachytherapy or proton beam therapy from 2004 to 2013 were obtained from the National Cancer Database. Logistic regression and propensity score matching was used to create a 1:1 matched cohort. Kaplan-Meier and Cox regression analyses were performed to evaluate survival in brachytherapy and proton groups.

Results: Median followup was 37 and 29 months for brachytherapy and protons, respectively. Most patients were treated with brachytherapy (n = 996) vs. protons (n = 228). Proton patients came from more urban, affluent, and educated zip codes, and they were more likely to be treated at an academic center (all p < 0.004). In the propensity-score matched cohort, 2-year overall survival was 97% vs. 93%, and 5-year overall survival was 77% vs. 51% for brachytherapy and protons, respectively (p = 0.008). Multivariate Cox regression found older age (hazard ratio [HR] = 1.06, 95% confidence interval (CI) = 1.03-1.09), larger tumor diameter (12-18 mm, HR = 2.48, 95% CI = 1.40-4.42, >18 mm, HR = 6.41, 95% CI = 1.45-28.35), and protons (HR = 1.89, 95% CI = 1.06-3.37) were negative prognosticators of survival.

Conclusions: Patients selected for proton treatment have inferior survival outcomes compared to brachytherapy in this retrospective analysis. There may be unaccounted variables that influence survival, warranting further prospective studies.

Citing Articles

Efficacy and safety of proton radiotherapy in treating choroidal melanoma: a systematic review and meta-analysis.

Miao Y, Zheng T, Zhang Q, Li M, Lei Q, Liu Q Radiat Oncol. 2025; 20(1):7.

PMID: 39799332 PMC: 11724514. DOI: 10.1186/s13014-024-02580-w.


Comparing efficacy of charged-particle therapy with brachytherapy in treatment of uveal melanoma.

Tseng Y, Hsu C, Chou Y Eye (Lond). 2024; 38(10):1882-1890.

PMID: 38565600 PMC: 11226678. DOI: 10.1038/s41433-024-03035-y.


Eye Plaque Brachytherapy for Choroidal Malignant Melanoma: A Case Report on the Use of Innovative Technology to Expand Access, Improve Practice, and Enhance Outcomes.

Mobit P, Yang C, Nittala M, He R, Ahmed H, Shultz G Cureus. 2024; 16(2):e54572.

PMID: 38524010 PMC: 10957294. DOI: 10.7759/cureus.54572.


Contemporary trends in management of uveal melanoma.

Chevli N, Zuhour R, Messer J, Haque W, Schefler A, Bernicker E J Contemp Brachytherapy. 2022; 14(2):123-129.

PMID: 35494177 PMC: 9044301. DOI: 10.5114/jcb.2022.115210.


Three-year outcomes of uveal melanoma treated with intra-operative ultrasound-guided iodine-125 brachytherapy using custom-built eye plaques.

Wong A, Teh B, Nguyen B, Pino R, Bretana M, Bernicker E J Contemp Brachytherapy. 2022; 14(2):130-139.

PMID: 35494176 PMC: 9044310. DOI: 10.5114/jcb.2022.115379.